Literature DB >> 8675859

Home treatment of patients with cystic fibrosis using the 'Intermate': the first year's experience.

E C Bramwell1, D M Halpin, F Duncan-Skingle, M E Hodson, D M Geddes.   

Abstract

Home treatment of patients with cystic fibrosis has many attractions and is becoming increasingly popular. The investigators have studied the use, results and costs of the first year of operation of a home-care intravenous antibiotic service using the 'Intermate' infusion device in a prospective study using questionnaires, spirometric and weight measurements. Ninety-three patients received 166 courses of intravenous antibiotics in full or in part at home during 1991. The average length of treatment was 12.5 days and on average 70% of the treatment was given at home. The mean percentage predicted FEV1 and FVC improved after treatment and the mean improvement was not significantly different to that produced by hospital treatment. Breathlessness, sputum volume, appetite, ability to sleep, mood, energy and overall well-being, as assessed by questionnaire, showed significant improvements after home treatment. The median time spent mixing and administering drugs was 10-19 hours and visiting the hospital was 7-12 hours. The median number of days of lost income to patients or their carers was 0 days. The majority of the patients were extremely satisfied with the treatment and supervision that they received. Using the home care service, 1442 inpatient days were saved. The investigators conclude that home care using 'Intermates' improves a patient's lung function and quality of life.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8675859     DOI: 10.1111/j.1365-2648.1995.tb03106.x

Source DB:  PubMed          Journal:  J Adv Nurs        ISSN: 0309-2402            Impact factor:   3.187


  4 in total

1.  Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes.

Authors:  J Michael Collaco; Deanna M Green; Garry R Cutting; Kathleen M Naughton; Peter J Mogayzel
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

2.  Adult cystic fibrosis patients' experiences of primary care consultations: a qualitative study.

Authors:  Karen Lowton; Karen D Ballard
Journal:  Br J Gen Pract       Date:  2006-07       Impact factor: 5.386

Review 3.  Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.

Authors:  Christian Krauth; Noushin Jalilvand; Tobias Welte; Reinhard Busse
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

4.  A prospective cohort study of the use of domiciliary intravenous antibiotics in bronchiectasis.

Authors:  Pallavi Bedi; Manjit K Sidhu; Lucienne S Donaldson; James D Chalmers; Maeve P Smith; Kim Turnbull; Joanna L Pentland; Jenny Scott; Adam T Hill
Journal:  NPJ Prim Care Respir Med       Date:  2014-10-23       Impact factor: 2.871

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.